Moving forward, page-2

3 upcoming ADO milestones that I am excited for:

1. June 2021 Saliva use case CE Mark update (see 17 May ASX Ann). If this is as accurate as our nasal swap results, surely this will be in high demand. I hope path to commercialisation is improved if this is the case, given the use case for saliva.
2. July - Sept (Q3) 2021: COVID-19 Flu A/B Multiplex Test Clinical trials (see p.10 Investor Presentation ASX Ann 28 April). If we sell this test to tackle the N Hemisphere flu season, it'll be a great Christmas for all.
3. "Late 2021": Collaborator 8 + their battery component manufacturer customers conducting AnteoX trials (see 26 April ASX Ann), which has proven ~18% improvement in their anode’s specific capacity. If these trials prove equally successful, with our "very large northern Asian diversified electronics manufacturer", we may just have a nice little Christmas present